Spontaneous inflammatory bowel disease (IBD) resembling human ulcerative colitis develops in mice mutant for the T cell receptor alpha gene (TCR-alpha-/-). TCR-alpha-/- mice lack TCR-alpha/beta+ cells but contain TCR-gamma/delta+ cells and a small population of a unique CD4+, TCR-alpha-/beta+(low) cells. Since all the immunoglobulin (Ig) classes are present in these mice, help to B cells must be provided by cells other than TCR-alpha/beta+ cells. In the present study, we found serum levels of IgG1 and IgG2 to be markedly increased in TCR-alpha-/- mice with IBD as compared to TCR-alpha-/- mice without IBD or TCR-alpha+/- controls. An increase in IgG1-, IgG2a- and IgA- but not IgM-secreting mesenteric lymph node (MLN) B cells was detected in TCR-alpha-/- mutant mice. There was also a marked increase in MLN B cells secreting autoantibody (IgG) to tropomyosin, a cytoskeletal protein. Examination of the hyperplastic MLN showed a marked increase in the number of B, TCR-delta+, and CD4+ TCR-alpha-/beta+ cells, similar to the cell population observed at the site of colonic inflammation. Analysis of spontaneous cytokine production by MLN cells using an enzyme-linked immunospot assay, immunohistochemistry, and reverse transcription/polymerase chain reaction showed a decrease of interleukin 2 (IL-2) but a marked increase of IL-4 and interferon gamma (IFN-gamma) production in TCR-alpha-/- mice with IBD as compared to TCR-alpha-/- mice without IBD and TCR alpha+/- control mice. Both TCR-alpha-/beta+ and TCR-delta+ cells were found to be capable of producing IL-4; IFN-gamma was produced mostly by non-T cells, many of which were shown to be CD3- NK 1.1+ cells. We propose that the cytokine imbalance present in these mice results in expansion of B cells, production and switching of autoantibodies to IgG2 subclass, and development of IBD. It is possible that the unusual CD4+ TCR-alpha-/beta+ population and expanded TCR-gamma/delta+ population present in TCR-alpha-/- mice plays a central role in this abnormal immune response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192355PMC
http://dx.doi.org/10.1084/jem.183.3.847DOI Listing

Publication Analysis

Top Keywords

tcr-alpha-/- mice
24
mice ibd
16
cells
14
mice
12
mln cells
12
marked increase
12
cytokine imbalance
8
mutant mice
8
inflammatory bowel
8
bowel disease
8

Similar Publications

Modifications to rhesus macaque TCR constant regions improve TCR cell surface expression.

PLoS One

January 2025

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.

T cell immunotherapy success is dependent on effective levels of antigen receptor expressed at the surface of engineered cells. Efforts to optimize surface expression in T cell receptor (TCR)-based therapeutic approaches include optimization of cellular engineering methods and coding sequences, and reducing the likelihood of exogenous TCR α and β chains mispairing with the endogenous TCR chains. Approaches to promote correct human TCR chain pairing include constant region mutations to create an additional disulfide bond between the two chains, full murinization of the constant region of the TCR α and β sequences, and a minimal set of murine mutations to the TCR α and β constant regions.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer-specific T cells often fail to eliminate tumors, so researchers explored using CD4 T cell receptors (CD4TCRs) from tumor-bearers for new treatments.
  • They focused on TCRs that target unique neoantigens presented by the surrounding tissue of MHC class II-negative cancer cells, testing the 11 most common TCRs.
  • Some TCRs shared similar structures despite different sequences, effectively attacking tumors and reversing tumor progression; choosing TCRs based on their genetic similarities may enhance therapeutic success.
View Article and Find Full Text PDF

Thymic atrophy marks the onset of immune aging, precipitating developmental anomalies in T cells. Numerous clinical and preclinical investigations have underscored the regulatory role of spores (GLS) in T cell development. However, the precise mechanisms underlying this regulation remain elusive.

View Article and Find Full Text PDF

Topical application of a BCL-2 inhibitor ameliorates imiquimod-induced psoriasiform dermatitis by eliminating senescent cells.

J Dermatol Sci

August 2024

Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, China; Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. Electronic address:

Background: Psoriasis is an inflammatory skin disease with unclear pathogenesis and unmet therapeutic needs.

Objective: To investigate the role of senescent CD4 T cells in psoriatic lesion formation and explore the application of senolytics in treating psoriasis.

Methods: We explored the expression levels of p16 and p21, classical markers of cellular senescence, in CD4 T cells from human psoriatic lesions and imiquimod (IMQ)-induced psoriatic lesions.

View Article and Find Full Text PDF

MAIT cell-MR1 reactivity is highly conserved across multiple divergent species.

J Biol Chem

June 2024

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address:

Mucosal-associated invariant T (MAIT) cells are a subset of unconventional T cells that recognize small molecule metabolites presented by major histocompatibility complex class I related protein 1 (MR1), via an αβ T cell receptor (TCR). MAIT TCRs feature an essentially invariant TCR α-chain, which is highly conserved between mammals. Similarly, MR1 is the most highly conserved major histocompatibility complex-I-like molecule.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!